BACKGROUND: Octreotide LAR is indicated for treatment of malignant carcinoid syndrome and has been studied at doses of 10 to 30 mg intramuscularly every 4 weeks. In clinical practice, higher doses are often prescribed for patients who experience refractory carcinoid syndrome (flushing and/or diarrhea) or tumor growth while on the maximum label-recommended dose. METHODS: We performed a retrospective, longitudinal review of octreotide LAR administration at a tertiary institution to determine the frequency of above-label dosing and outcomes. RESULTS: Three hundred thirty-eight patients were considered evaluable, among whom 100 (30%) underwent at least 1 increase in dose or frequency of octreotide-LAR above the standard label dose. The most common maximum doses were 40 mg every 4 weeks (n = 37 patients), 60 mg every 4 weeks (n = 34), and 30 mg every 3 weeks (n = 18). The indications for dose increase were worsening carcinoid syndrome (n = 60), radiographic progression (n = 33), and rising urine 5-HIAA (n = 6). Of the patients whose doses were increased for refractory carcinoid syndrome, 62% (n = 34) experienced improvement in diarrhea, and 56% (n = 28) experienced improvement in flushing. CONCLUSIONS: In conclusion, octreotide LAR is commonly prescribed in doses or schedules above the recommended dose and frequency. Patients with refractory carcinoid syndrome appear to experience a clinical benefit from this change. Prospective data may be used to further evaluate this strategy.
BACKGROUND: Octreotide LAR is indicated for treatment of malignant carcinoid syndrome and has been studied at doses of 10 to 30 mg intramuscularly every 4 weeks. In clinical practice, higher doses are often prescribed for patients who experience refractory carcinoid syndrome (flushing and/or diarrhea) or tumor growth while on the maximum label-recommended dose. METHODS: We performed a retrospective, longitudinal review of octreotide LAR administration at a tertiary institution to determine the frequency of above-label dosing and outcomes. RESULTS: Three hundred thirty-eight patients were considered evaluable, among whom 100 (30%) underwent at least 1 increase in dose or frequency of octreotide-LAR above the standard label dose. The most common maximum doses were 40 mg every 4 weeks (n = 37 patients), 60 mg every 4 weeks (n = 34), and 30 mg every 3 weeks (n = 18). The indications for dose increase were worsening carcinoid syndrome (n = 60), radiographic progression (n = 33), and rising urine 5-HIAA (n = 6). Of the patients whose doses were increased for refractory carcinoid syndrome, 62% (n = 34) experienced improvement in diarrhea, and 56% (n = 28) experienced improvement in flushing. CONCLUSIONS: In conclusion, octreotide LAR is commonly prescribed in doses or schedules above the recommended dose and frequency. Patients with refractory carcinoid syndrome appear to experience a clinical benefit from this change. Prospective data may be used to further evaluate this strategy.
Authors: Kathleen I Pritchard; Lois E Shepherd; Judith-Anne W Chapman; Brian D Norris; Jacques Cantin; Paul E Goss; Susan F Dent; David Walde; Ted A Vandenberg; Brian Findlay; Susan E O'Reilly; Carolyn F Wilson; Lei Han; Ettie Piura; Timothy J Whelan; Michael N Pollak Journal: J Clin Oncol Date: 2011-09-12 Impact factor: 44.544
Authors: J Rubin; J Ajani; W Schirmer; A P Venook; R Bukowski; R Pommier; L Saltz; P Dandona; L Anthony Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Matthew H Kulke; Al B Benson; Emily Bergsland; Jordan D Berlin; Lawrence S Blaszkowsky; Michael A Choti; Orlo H Clark; Gerard M Doherty; James Eason; Lyska Emerson; Paul F Engstrom; Whitney S Goldner; Martin J Heslin; Fouad Kandeel; Pamela L Kunz; Boris W Kuvshinoff; Jeffrey F Moley; Venu G Pillarisetty; Leonard Saltz; David E Schteingart; Manisha H Shah; Stephen Shibata; Jonathan R Strosberg; Jean-Nicolas Vauthey; Rebekah White; James C Yao; Deborah A Freedman-Cass; Mary A Dwyer Journal: J Natl Compr Canc Netw Date: 2012-06-01 Impact factor: 11.908
Authors: J Philip Boudreaux; David S Klimstra; Manal M Hassan; Eugene A Woltering; Robert T Jensen; Stanley J Goldsmith; Charles Nutting; David L Bushnell; Martyn E Caplin; James C Yao Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Michael S Broder; David Beenhouwer; Jonathan R Strosberg; Maureen P Neary; Dasha Cherepanov Journal: World J Gastroenterol Date: 2015-02-14 Impact factor: 5.742
Authors: Jonathan R Strosberg; Thorvardur R Halfdanarson; Andrew M Bellizzi; Jennifer A Chan; Joseph S Dillon; Anthony P Heaney; Pamela L Kunz; Thomas M O'Dorisio; Riad Salem; Eva Segelov; James R Howe; Rodney F Pommier; Kari Brendtro; Mohammad A Bashir; Simron Singh; Michael C Soulen; Laura Tang; Jerome S Zacks; James C Yao; Emily K Bergsland Journal: Pancreas Date: 2017-07 Impact factor: 3.327
Authors: Jonathan R Strosberg; Al B Benson; Lynn Huynh; Mei Sheng Duh; Jamie Goldman; Vaibhav Sahai; Alfred W Rademaker; Matthew H Kulke Journal: Oncologist Date: 2014-08-05
Authors: Jessica J Jalbert; Roman Casciano; Jie Meng; Lauren K Brais; Sonia J Pulgar; Anthony Berthon; Jerome Dinet; Matthew H Kulke Journal: Oncologist Date: 2020-01-30
Authors: Krystallenia I Alexandraki; Aggeliki Karapanagioti; Ioannis Karoumpalis; Georgios Boutzios; Gregory A Kaltsas Journal: Biomed Res Int Date: 2017-11-19 Impact factor: 3.411